Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction

Cardiovascular Research

Volumn 41, Issue 3, 1999, Pages 544-553

  Marie, Christine ^a   Mossiat, Claude ^a   Gros, Claude ^b   Schwartz, Jean Charles ^b   Lecomte, Jeanne Marie ^c   Bralet, Jean ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b CENTRE PAUL BROCA   (France)

^c Laboratoire Bioprojet   (France)

Author keywords

Angiotensin converting enzyme; Fasidotril; Myocardial infarction; Neprilysin; Rat

Indexed keywords

ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; FASIDOTRIL; MEMBRANE METALLOENDOPEPTIDASE; RENIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; LONG TERM CARE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; SURVIVAL;

ALANINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; HEART RATE; MALE; MYOCARDIAL INFARCTION; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; PROTEASE INHIBITORS; RATS; RATS, WISTAR; RENIN; SURVIVAL RATE; TIME FACTORS;

EID: 0033025012     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00257-0     Document Type: Article

References (69)

1. Francis G.S., Goldschmith S.R., Levine B., Olivari M.T., Conn J.N. The neurohumoral axis in congestive heart failure. Ann Intern Med. 101:1984;370-377.
2. Gavras H., Gavras L. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens. 1:1991;385-392.
3. Kiowski W., Sütsch G., Dösseger L. Clinical benefits of angiotensin-converting enzyme inhibitors in chronic heart failure. J Cardiovasc Pharmacol. 27(Suppl. 2):1996;S19-S24.
4. Brenner B.M., Ballermann B.J., Gunning M.E., Zeidel M.L. Diverse biological actions of atrial natriuretic peptide. Physiol Rev. 70:1990;665-690.
5. Bates E.R., Shenker Y., Grekin R.J. The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. Circulation. 73:1986;1155-1161.
6. Eiskjaer H., Bagger J.P., Danielsen H.et al. Attenuated renal excretory responses to atrial natriuretic peptide in congestive heart failure in man. Int J Cardiol. 33:1991;71-74.
7. Scriven T.A., Burnett J.C. Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation. 72:1985;892-897.
8. Kohzuki M., Hodsman G.P., Johnston C.I. Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol. 256:1989;H533-H538.
9. Drexler H., Hirth C., Stasch H.P.et al. Vasodilatory action of atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. Circ Res. 66:1990;1371-1380.
10. Cody R.J., Atlas S.A., Laragh J.H.et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 78:1986;1362-1374.
11. Giles T.D., Quiroz A.C., Roffidal L.E., Marder H., Sander G.E. Prolonged hemodynamic benefits from a high-dose bolus injection of human atrial natriuretic factor in congestive heart failure. Clin Pharmacol Ther. 50:1991;557-563.
12. Dubois-Rande J.L., Adnot S., Benvenuti C.et al. Hemodynamic response to intracoronary infusion of atrial natriuretic factor in patients with normal or altered left ventricular function. J Cardiovasc Pharmacol. 17:1991;608-614.
13. Northridge D.B., Jardine A.G., Alabaster C.T.et al. Effects of UK 69 578: A novel atriopeptidase inhibitor. Lancet. 2:1989;591-593.
14. Kahn J.C., Patey M., Dubois-Rande J.L.et al. Sinorphan, an orally-active enkephalinase inhibitor, enhances plasma atrial natriuretic factor in severe congestive heart failure. Lancet. 335:1990;118-119.
15. Kimmelstiel C.D., Perrone R., Kilcoyne L.et al. Effects of renal neutral endopeptidase on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Cardiology. 87:1996;46-53.
16. Schwartz J.C., Gros C., Lecomte J.M., Bralet J. Minireview: Enkephalinase (EC 3.4.24.11) inhibitors: Protection of ANF against inactivation and potential therapeutic applications. Life Sci. 47:1990;1279-1297.
17. Roques B.P., Noble F., Daugé V., Fournié-Zaluski M.C., Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 45:1993;87-145.
18. Margulies K.B., Perrella M.A., McKinley L.J., Burnett J.C. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest. 88:1991;1636-1642.
19. Seymour A.A., Asaad M.M., Lanoce V.M.et al. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther. 266:1993;872-883.
20. Trippodo N.C., Fox M., Natarajan V.et al. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther. 267:1993;108-116.
21. Bralet J., Marie C., Mossiat C.et al. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. J Pharmacol Exp Ther. 270:1994;8-14.
22. Marie C., Mossiat C., Lecomte J.M., Schwartz J.C., Bralet J. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. J Pharmacol Exp Ther. 275:1995;1324-1331.
23. Gonzalez W., Beslot F., Laboulandine I.et al. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exp Ther. 278:1996;573-581.
24. Trippodo N.C., Robl J.A., Asaad M.M.et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS- 182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 275:1995;745-752.
25. Pfeffer J.M., Pfeffer M.A., Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 57:1985;84-95.
26. Selye H., Bajuzs E., Grasso S., Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology. 11:1960;398-407.
27. Chien Y.W., Barbee R.W., MacPhee A.A., Frohlich E.D., Trippodo N.C. Increased ANF secretion after volume expansion is preserved in rats with heart failure. Am J Physiol. 254:1988;R185-R191.
28. Michel J.B., Lattion A.L., Salzman J.L.et al. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res. 62:1988;641-650.
29. Carmel A., Yaron A. An intramolecularly quenched fluorescent tripeptide as a fluorogenic substrate of angiotensin I-converting enzyme and of bacterial dipeptidyl carboxypeptidase. Eur J Biochem. 87:1978;265-273.
30. Giros B., Gros C., Schwartz J.C.et al. Enantiomers of thiorphan and acetorphan: Correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effects. J Pharmacol Exp Ther. 243:1987;666-673.
31. Gros C., Noel N., Souque A.et al. Mixed inhibitors of angiotensin-converting enzymes (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA. 88:1991;4210-4214.
32. Lehr D., Goldman H.W., Casner P. Renin-angiotensin role in thirst: paradoxical enhancement of drinking by angiotensin converting enzyme inhibition. Science. 182:1973;791-793.
33. Jeremic G., Masson S., Luvara G.et al. Effects of a new angiotensin-converting enzyme inhibitor (idapril) in rats with left ventricular dysfunction after myocardial infarction. J Cardiovasc Pharmacol. 27:1996;347-354.
34. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 72:1985;406-412.
35. Sweet C.S., Emmert S.E., Stabilito I.I., Ribeiro L.G.T. Increased survival in rats with congestive heart failure treated with enalapril. J Cardiovasc Pharmacol. 10:1987;636-642.
36. Wollert K.C., Studer R., von Bülow B., Drexler H. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation. 90:1994;2457-2467.
37. Fishbein M.C., Maclean D., Maroko P.R. Experimental infarction in the rat. Qualitative and quantitative changes during pathologic evolution. Am J Pathol. 90:1978;57-70.
38. Gay R.G. Early and late effects of captopril treatment after large myocardial infarction in rats. J Am Coll Cardiol. 16:1990;967-977.
39. Raya T.E., Gay R.G., Aguirre M., Goldman S. Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: A comparison of captopril and hydralazine. Circ Res. 64:1989;330-337.
40. Dzau V.J. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol. 70:1992;4C-11C.
41. Hirsch A.T., Talness C.E., Shunkert H., Paul M., Dzau V.J. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 69:1991;475-482.
42. Aceto J.F., Baker K.M. (Sar)angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol. 259:1990;H806-H813.
43. Baker K.M., Chermin M.I., Wixson S.K., Aceto J.F. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 259:1990;H324-H332.
44. Piedimonte G., Nadel J.A., Long C.S., Hoffman J.I.E. Neutral endopeptidase in the heart. Circ Res. 75:1994;770-779.
45. Appel R.A. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol. 262:1992;F911-F918.
46. Monopoli A., Ongini E., Cigola E., Olivetti G. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 20:1992;496-504.
47. Marie C., Mossiat C., Gros C., Monteil T., Bralet J. Effect of prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction. Cardiovasc Drugs Ther. 10:1996;593-598.
48. Schunkert H., Ingelfinger J.R., Hirsch A.T.et al. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res. 72:1993;312-318.
49. Hirsch A.T., Talsness C.E., Smith A.D.et al. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation. 86:1992;1566-1574.
50. Huang H., Arnal J.F., Llorens-Cortes C.et al. Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental heart failure. A novel aspect of endothelium dysfunction. Circ Res. 75:1994;454-461.
51. Fyhrquist F., Forslund T., Tikkanen I., Grönagen-Riska C. Induction of angiotensin I-converting enzyme in rat lung with captopril (SQ 14225). Eur J Pharmacol. 67:1980;473-475.
52. Kobubu T., Ueda E., Ono M.et al. Effects of captopril (SQ 14,225) on the renin-angiotensin-aldosterone system in normal rats. Eur J Pharmacol. 62:1980;269-275.
53. Grönagen-Riska C., Forslund T., Hortling L., Fyhrquist F. Increase of serum and membrane-bound angiotensin-converting enzyme by captopril (SQ 14225) treatment. Acta Med Scand. 677:1983;101-104.
54. Helin K., Tikkanen I., Hohenthal U., Fyhrquist F. Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes. Eur J Pharmacol. 264:1994;135-141.
55. Naftilan A.J., Oparil S. Inhibition of renin release from rat kidney slices by the angiotensins. Am J Physiol. 235:1978;F62-F68.
56. Barrett G.L., Morgan T.O., Smith M., Alcorn D., Aldred P. Effect of converting enzyme inhibition on renin synthesis and secretion in mice. Hypertension. 14:1989;385-395.
57. Kurtz A., Della-Bruna R., Pfeilshister J., Taugner R., Bauer C. Atrial natriuretic peptide inhibits renin release from isolated renal juxtaglomerular cells by a cGMP mediated process. Proc Natl Acad Sci USA. 83:1986;4769-4773.
58. Cody R.J., Atlas S.A., Laragh J.H.et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 78:1986;1362-1374.
59. Münzel T., Kurtz S., Holtz J.et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation. 86:1992;1089-1098.
60. Wada A., Tsutamoto T., Matsuda Y., Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation. 89:1994;2232-2240.
61. Kanamori T., Wada A., Tsutamoto T., Kinoshita M. Possible regulation of renin release by ANP in dogs with heart failure. Am J Physiol. 269:1995;H2281-H2287.
62. Trippodo N.C., Panchal B.C., Fox M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition of heart failure. J Pharmacol Exp Ther. 272:1995;619-627.
63. Welches W.R., Brosnihan K.B., Ferrario M.C. Minireview: A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 52:1993;1461-1480.
64. Abassi Z.A., Tate J.E., Golomb E., Keiser H.R. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 20:1992;89-95.
65. Mendez R.E., Dunn B.R., Troy J.L., Brenner B.M. Modulation of the natriuretic response to atrial natriuretic peptide by alterations in peritubular Starling forces in the rat. Circ Res. 59:1986;605-611.
66. Ritz E., Nowack R. Detrimental and beneficial effects of converting enzyme inhibitors on the kidney. J Cardiovasc Pharmacol. 16(Suppl. 4):1990;S70-S75.
67. Cleland J.G.F., Henderson E., McLenachan J.et al. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol. 17:1991;733-739.
68. Ambrosioni E., Borghi C., Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: Safety considerations. Am J Cardiol. 68:1991;101D-110D.
69. Squire I.B., MacFadyen R.J., Reid J.L., Devlin A., Lees K.R. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol. 27:1996;657-666.